Havrix

Havrix is an injectable vaccine containing inactivated hepatitis A virus (with algeldrate as an excipient). It is supplied as a sterile solution for intramuscular use, marketed in the European Union. The product is prescribed to stimulate active immunity against hepatitis A infection. The vaccine is administered as a single dose or as part of a two‑dose schedule, depending on the vaccination program, and is classified as a prescription‑only product.

Havrix is indicated for the prevention of hepatitis A infection in individuals who have not been previously immunized.

- Active immunization of adults and children aged 12 months and older. - Protection of travelers to regions with high hepatitis A endemicity. - Prevention of outbreaks in community settings such as schools or camps. - Immunization of persons with occupational exposure to hepatitis A virus, e.g., laboratory workers.

Following intramuscular injection, Havrix may cause transient local or systemic reactions; most are mild and resolve without intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or malaise. - Nausea. - Muscle aches.

Serious: - Severe allergic reaction (anaphylaxis). - Guillain‑Barré syndrome (rare). - High fever. - Persistent joint pain.

Healthcare providers should assess individual risk factors and medical history before administering Havrix to ensure safe and effective vaccination.

- Not recommended for persons with known severe allergy to any vaccine component. - Use with caution in individuals with a history of hypersensitivity to gelatin or egg proteins. - Delay vaccination in moderate or severe acute illness. - Consult a physician for pregnant or breastfeeding women; safety data are limited. - Post‑vaccination serology may be considered for immunocompromised patients. - Observe for at least 15 minutes after injection for immediate reactions.

Havrix does not have many documented drug‑drug interactions, but certain conditions may influence its administration or immune response.

Avoid: - Concomitant administration of other live vaccines within 4 weeks. - Use of immunoglobulin products within 2 weeks before or after vaccination (may reduce antibody response).

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish vaccine efficacy. - Chronic liver disease may require adjusted dosing schedule. - Antipyretics can be taken to manage mild fever or pain after vaccination.